Top Markets
#1 Islamic Coin Islamic Coin +152.33%
#2 Bitway Bitway +44.68%
#3 Starpower Starpower +39.27%
#4 Wrapped STX (Velar) Wrapped STX (Velar) +32.03%
#5 aelf aelf +25.83%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.23%
#7 Pons Pons +22.58%
#8 SkyAI SkyAI +18.92%
#9 Ocean Protocol Ocean Protocol +16.20%
#10 Bedrock Bedrock +15.52%
Coin of the day
Islamic Coin Islamic Coin
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Medivir AB (publ) Medivir AB (publ)

Medivir AB (publ)

MVIR-B
Classement en actions #29651
Medivir AB (publ) is a pharmaceutical company established in 1987 and... Medivir AB (publ) is a pharmaceutical company established in 1987 and headquartered in Huddinge, Sweden. It is dedicated to the research, development, and global commercialization of medicines, with a primary focus on oncology. The company currently markets Zoviduo (formerly Xerclear) for the treatment of labial herpes. Its robust development pipeline includes Remetinostat, targeting MF cutaneous T-cell lymphoma and basal cell carcinoma; MIV-818, aimed at liver cancer; and MIV-711, being advanced for osteoarthritis. Additionally, Medivir is progressing Birinapant and IGM-8444 for various solid tumor indications. Collaborative efforts are also key to its strategy, including a research partnership with SciLifeLab's Drug Discovery and Development Platform to discover antivirals for SARS CoV-2, alongside licensing agreements with Tango Therapeutics for a preclinical research program and with Ubiquigent Limited for the USP7 preclinical research program.
Prix de l'action
$0.68377137
Dernière synchronisation: 2023-05-23
Capitalisation boursière
$20.23M
Changement (1 jour)
-0.60%
Changement (1 an)
0.00%
Pays
SE
Échange Medivir AB (publ) (MVIR-B)

Catégorie

Healthcare
Ratio P/S pour Medivir AB (publ) (MVIR-B)
Ratio P/S au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Medivir AB (publ), le ratio cours/ventes actuel (TTM) est 0. À la fin de 2026, le ratio P/S était de 0.
Historique du ratio P/S pour Medivir AB (publ) de 2026 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
Pas assez de données pour les dates fournies.
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR